Concepedia

Anella Yahiaoui

AY

Statistics

Publications

6

Citations

271

H-Index

6

Active since

2017

Affiliations

Gilead Sciences (United States)(Current)

Consorci Institut D'Investigacions Biomediques August Pi I Sunyer

Centro de Investigación Biomédica en Red de Cáncer

Hospital Clínic de Barcelona

Universitat de Barcelona

Anella Yahiaoui is an author at Gilead Sciences (United States) specializing in oncology, molecular oncology, and pi3k inhibitors.

Publications per year

2017–2021

6

Publications

6

The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma

Juan García Valero, Alba Matas‐Céspedes, Fabián Arenas et al. · Leukemia · 2021 · 66 citations · Full text

, , +17

IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia

Annika Scheffold, Billy Michael Chelliah Jebaraj, Eugen Tausch et al. · Blood · 2019 · 55 citations · Full text

, , +17

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors

Anella Yahiaoui, Sarah Meadows, Rick Sorensen et al. · PLoS ONE · 2017 · 51 citations · Full text

, , +16

Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia

Joseph P. Loftus, Anella Yahiaoui, Patrick A. Brown et al. · Haematologica · 2020 · 36 citations · Full text

, , +17

PI3Kδ inhibition reshapes follicular lymphoma–immune microenvironment cross talk and unleashes the activity of venetoclax

Neus Serrat, Martina Guerrero‐Hernández, Alba Matas‐Céspedes et al. · Blood Advances · 2020 · 34 citations · Full text

, , +15

1–5 of 6